The Asia-Pacific Nuclear Imaging Market was worth $3.13 billion in 2016 and estimated to be growing at a CAGR of 9.64%, to reach $4.96 billion by 2021. Medical imaging is the method of generating a photographic image of the inside of the body for medical intervention. These devices aid in creating a databank of normal anatomy and physiology of internal organs so that any irregularity can be observed immediately.
Nuclear imaging is most commonly utilized for cardiovascular and oncology applications. It refers to the method of generating visuals of the organs of the body by processing minor quantity of radioactive tracers. The images are obtained using a gamma camera and can be documented on film or on a computer.
Browse market data tables and in-depth TOC of the Asia-Pacific Nuclear Imaging Market to 2021 @ http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-imaging-market-1626/
The growth of the Asia-Pacific Nuclear Imaging market is mainly due to factors such as an increase in the number of cancer and cardiovascular disease cases, predilection towards minimally invasive procedures, ready availability of radiopharmaceuticals, and improving healthcare infrastructure in developing markets. However, factors such as costly procedures & equipment, inadequate number of trained medical staff, and shortage of supplies are hampering the growth of the market in this region.
The Asia-Pacific Nuclear Imaging market is segmented based on Diagnostic Technologies and Application. The market for Nuclear Imaging, on the basis of Diagnostic Technologies is segmented into PET Radioisotopes and SPECT Radioisotopes. PET Radioisotopes are further segmented into Rubidium-82, Fluorine-18, whereas SPECT Radioisotopes are further segmented into Thallium-201, Technetium-99m, Xenon-133, and Iodine-123. On the basis of Application, the Nuclear Imaging market is segmented into PET and SPECT. PET is further segmented into Cardiology, Oncology, and Neurology, whereas SPECT is segmented into Lymphoma, Neurology, Cardiology, and Thyroid. PET is mainly being utilized in oncology due to superior quality of imaging; Whereas SPECT is used in the cardiology section accounting for almost 80% of the entire cardiology market share.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-imaging-market-1626/request-sample
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Among Asia-Pacific countries, India, Japan, and Australia will be the substantial markets due to growing healthcare budgets and rising popularity of several radiopharmaceuticals in numerous clinical indications.
Companies are showing a strong interest in enhancing image quality by developing new technologies and creating new devices or novel techniques to achieve images with higher spatial resolution. The major companies dominating the Nuclear Imaging market in this region are Mallinckrodt plc, Siemens Medical Solutions, Hitachi Medical Corporation, Medtronic Inc., General Electric Co. (healthcare division), IBA Group, Positron Corporation, Philips Medical Systems, Naviscan, Toshiba Medical Systems Corporation, Carestream Health, Lantheus Medical Imaging Inc., Cardinal Health Inc., and Bayer AG.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases